We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+45.54%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
-$48M
Cap. Flow
-$51.8M
Cap. Flow %
-39.17%
Top 10 Hldgs %
58.69%
Holding
110
New
19
Increased
5
Reduced
6
Closed
42

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$9.06M
2
GRI
GRI Bio
GRI
+$8.89M
3
IMGN
Immunogen Inc
IMGN
+$5.73M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.5M
5
JSPR icon
Jasper Therapeutics
JSPR
+$4.26M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$8.15M
2
ACLX
Arcellx
ACLX
+$4.62M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$4.58M
4
GKOS icon
Glaukos
GKOS
+$4.56M
5
PEN icon
Penumbra
PEN
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Financials 1.18%
3 Technology 1.18%
4 Communication Services 0.44%
5 Materials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTMWW
76
DELISTED
Bitcoin Depot Inc Warrant
BTMWW
– –
-50,000
Closed -$2K
CVRX icon
77
CVRx
CVRX
$158M
– –
-205,000
Closed -$1.91M
GKOS icon
78
Glaukos
GKOS
$10.1B
– –
-91,000
Closed -$4.56M
ILMN icon
79
Illumina
ILMN
$29.3B
– –
-9,252
Closed -$2.09M
INSP icon
80
Inspire Medical Systems
INSP
$1.7B
– –
-12,500
Closed -$2.93M
KRMD icon
81
KORU Medical Systems
KRMD
$164M
– –
-685,002
Closed -$2.89M
LUCYW icon
82
Innovative Eyewear Inc Series A Warrants 8/16/27
LUCYW
$129K
– –
-122,400
Closed -$44.8K
MDXG icon
83
MiMedx Group
MDXG
$609M
– –
-748,000
Closed -$2.55M
MYGN icon
84
Myriad Genetics
MYGN
$304M
– –
-180,000
Closed -$4.18M
NEO icon
85
NeoGenomics
NEO
$2B
– –
-240,000
Closed -$4.18M
NVCR icon
86
CALL
NovoCure
NVCR
$1.83B
– –
-161,500
Closed -$9.71M
PACB icon
87
Pacific Biosciences
PACB
$363M
– –
-178,000
Closed -$2.06M
PCVX icon
88
Vaxcyte
PCVX
$8.5B
– –
-43,000
Closed -$1.61M
PEN icon
89
Penumbra
PEN
$12.8B
– –
-16,000
Closed -$4.46M
REVB icon
90
Revelation Biosciences
REVB
$4.38M
– –
-6
Closed -$48.4K
RMD icon
91
ResMed
RMD
$32.4B
– –
-17,000
Closed -$3.72M
VREX icon
92
Varex Imaging
VREX
$516M
– –
-165,000
Closed -$3M
VRNA
93
DELISTED
Verona Pharma
VRNA
– –
-25,000
Closed -$502K
VTYX
94
DELISTED
Ventyx Biosciences
VTYX
– –
-55,000
Closed -$1.84M
WGS icon
95
GeneDx Holdings
WGS
$2.08B
– –
-139,030
Closed -$1.67M
MITA
96
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
– –
-85,000
Closed -$872K
ADRT
97
DELISTED
Ault Disruptive Technologies Corporation
ADRT
– –
-150,000
Closed -$1.57M
SILK
98
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-45,000
Closed -$1.76M
CSSE
99
DELISTED
Chicken Soup for the Soul Entertainment, Inc. Class A Common Stock
CSSE
– –
-212,164
Closed -$424K
MRNS
100
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-228,714
Closed -$1.58M
1 2 3
4
5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Altium Capital Management held 110 positions worth $132M, down 27% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Altium Capital Management withdrew a net $51.8M in Q2 2023, closing 42 positions and reducing 6 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Xenon Pharmaceuticals worth $8.78M.

  • Altium Capital Management's largest Q2 2023 buy was Xenon Pharmaceuticals: 228,000 shares worth $8.78M.
  • Altium Capital Management added most to Harmony Biosciences in Q2 2023, an estimated $4.14M increase.
  • Altium Capital Management's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $1.82M.
  • Altium Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
  • Altium Capital Management's ten largest holdings make up 59% of its $132M portfolio in Q2 2023.
  • Altium Capital Management opened 19 new positions and closed 42 in Q2 2023.
  • Altium Capital Management's portfolio value fell 27% quarter-over-quarter to $132M.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.